Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preliminary Evaluation of Dalbavancin's Efficacy in People Who Use Drugs With Severe Gram-positive Infections

NCT04847921 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT04847921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04847921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preliminary Evaluation of Dalbavancin's Efficacy in People Who Use Drugs With Severe Gram-positive Infections
Lead sponsor
University of Colorado, Denver
Phase
Phase 2/3
Overall status
Terminated
Start date
April 30, 2021
Completion date
October 5, 2023
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gram-positive bacteraemia, gram-positive bacterial infections, intravenous substance abuse, substance use disorders